At signing, the peak-sales model looks solid. Assumptions are defensible. Benchmarks are cited. The curve supports the upfront, the milestones, and the investment memo. Governance signs off. Post-close, the story starts to change. Not dramatically. Quietly. Early uptake comes in below plan. Market access stretches beyond forecast. Competitor timelines compress. None of this triggers a formal reset. The peak number remains untouched. Peak-sales models rarely collapse in one moment. They erode while staying officially alive. The early divergence everyone sees Within the first 6–12 months post-close, most BD and alliance teams see the same signals. Sales force feedback doesn’t match…
Author: sagarmahajan2886@gmail.com
The deck said “strategic fit.” The IC approved. The press release landed. Twelve months later, the asset is quietly deprioritized, milestones slip, and portfolio reviews start using softer language like “optional,” “non-core,” or “revisit later.” What looked aligned at signing unravels not because the science failed, but because the fit was narrative-led rather than execution-tested. This failure mode shows up repeatedly in Pharma BD & Licensing. Teams convince themselves the deal fits the portfolio story, but the post-close operating reality tells a different story. By the time that gap is visible, value erosion is already locked in. Strategic fit is…
Local pricing autonomy rarely disappears overnight. It gets engineered out at deal sign-off. At signing, global price corridors are locked to close the transaction. Local tender dynamics, reference pricing spillovers, and access trade-offs are consciously deferred. The assumption is that affiliates will manage these later. What affiliates actually inherit post-handover is a fixed pricing logic they did not shape. Where pricing autonomy is really lost The loss of flexibility happens structurally, not accidentally. Once global corridors are agreed, every local pricing decision becomes constrained by spillover risk elsewhere in the portfolio. Discounts stop being commercial tools and turn into binary…
Undefined control rights create post-close decision limbo, delaying milestones and eroding alliance value.
How optimistic CMC assumptions create post-approval margin resets and governance failures
In most licensing auctions, the cross-functional valuation model becomes the silent failure point that no one admits to, driving a predictable 15–30% valuation drift and forcing BD leads into late-stage renegotiations that damage board credibility. When assumptions fragment across Functions, your risk isn’t theoretical — it’s a direct 10–20% overpayment or a blown walk-away moment that follows you for years. Join the Weekly Pharma BD Signals newsletter for execution checklists and deal-room breakdowns.Where the Overpayment Drift Starts Valuation drift begins the moment Finance, MAx, CMC, and Regulatory each build their own spreadsheets. No one disputes the science — they dispute…
How unmodellable COGS inflation drives 15–30% valuation drift and post-deal margin loss.
The silent valuation trap in co-development deals—and how BD teams prevent hidden downside from milestone flaws.
The Hidden Premium Problem Mid-size pharma companies frequently walk into competitive licensing processes convinced they are bidding rationally, only to discover post-deal that they have paid 20–40% above what later data justified. The challenge is not lack of financial discipline—it is structural blind spots in competitive intelligence, internal incentive systems, and risk translation during accelerated auctions. Where the Auction Dynamics Break Down Shallow competitor reads: BD (Business Development) teams often extrapolate competitor interest from outdated pipeline benchmarks or broad strategic statements rather than active transaction patterns, therapeutic area build-out, or internal capacity constraints of rivals. Unvetted assumptions on global expansion…
Intro: When “positive” data isn’t enough for price Teams celebrate a Phase 3 readout: primary endpoint met, safety clean, filing on track. But the mood changes once pricing and HTA teams start modelling. The comparator used in the pivotal trial doesn’t align with real-world standard of care in major markets. Suddenly the asset struggles to show incremental value. HTAs downgrade the evidence. Payers push for deep discounts. A program that looked “de-risked” hits a commercial wall. This is more common than people admit—especially in global programs trying to reconcile FDA expectations with EU access realities. Why this happens in real…